Research programme: fibrin-derived peptides - FIBREX Medical/Mallinckrodt
Alternative Names: FX 07; FX 08; FX 107; FX 201; FX 300 SeriesLatest Information Update: 16 Jul 2016
At a glance
- Originator FIBREX Medical
- Developer FIBREX Medical; Mallinckrodt plc
- Class Peptides
- Mechanism of Action Cadherin 5 modulators; Fibrin inhibitors; Fibrin modulators; Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute lung injury; Adult respiratory distress syndrome; Dengue; Haematological disorders; Inflammation; Sepsis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-lung-injury in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dengue in USA